It could be rightly said that Pharmacyte Biotech Inc (OTCMKTS:PMCB) is just making the right moves to establish itself as a long-term player in the healthcare space. After becoming a part of a major research paper, the company noted the appointment of Thomas Liquard as its Board of Directors, who will also become the Chairman of the Audit Committee.
Appointment Of Thomas Liquard
The addition of Liquard into the Board of Directors hold significance for Pharmacyte Biotech Inc (OTCMKTS:PMCB), which is particularly on account of Liquard’s experience track record. Liquard’s extensive hold in the pharmaceutical industry comes from his past work experiences at Alchemia Limited and Pfizer Inc. (NYSE:PFE). Liquard had served Alchemia Ltd as CEO, while he was Senior Director, Portfolio Development Leader Emerging Markets for the Established Products Porfolio at Pfizer in New York. Pharmacyte Biotech Inc (OTCMKTS:PMCB) anticipates to gain tremendously from the past experiences of Liquard at the two pharmaceutical majors.
Mentioned in a research paper
Pharmacyte Biotech Inc (OTCMKTS:PMCB) gained momentum after a research undertaken by Prof. Ann Simpson and her colleagues established that the company’s patented encapsulation technology can reverse Diabetes. The paper titled, “Reversal of diabetes following transplantation of an insulin-secreting human liver cell line: Melligen Cells,” threw light on how the company’s unique cell-in-a-Box technology can prevent Melligen cells from being rejected by the body’s immune system. The research concluded that Melligen cells can reverse Type-1 diabetes if Melligen cells are encapsulated before introducing in the human system.
Thus, the research has put the focus back on Pharmacyte Biotech Inc (OTCMKTS:PMCB) by validating its technology and efficiency in treating Diabetes. It is to be noted that the company is also developing treatments for cancer through the same live-cell encapsulation technology. The stock of the company closed 1.16% lower at $0.154 on Tuesday while an average of 2.86 million shares traded on the day.